Abstract
Radionuclide imaging of endocrine diseases has been in clinical application for many years. Over the past six decades, an increasing number of radionuclides and radiolabeled compounds are available for imaging the endocrine organs/tissues functions. Radionuclide imaging provides functional as well as morphological information on multiple endocrine organs especially thyroid, parathyroid, and adrenal glands. Endocrine nuclear medicine includes not only diagnosis but also internal radionuclide therapy. Recently, radiolabeled peptides have also been used for diagnostic and for therapeutic purposes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Alenezi S, Asa'ad S, Elgazzar A (2015) Scintigraphic parathyroid imaging: concepts and new developments. Res Rep Nucl Med 2015(5):9–18
Elgazzar A, Alenezi S, Alshammari J et al (2015) Value of oblique view in nodular thyroid disease; revisiting fundamentals. World J Nucl Med 14(2):125–127
Elgazzar AH, Gelfand MJ, Washburn LC, Clark J, Nagaraj N, Cumming D, Hughes J, Maxon HR (1995) 1-123 MIBG scintigraphy in adults – a report of clinical experience. Clin Nucl Med 20:147–152
Franklyn JA (2009) What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and management of hyperthyroidism? Clin Endocrinol 72:11–12
Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, Prigent A, Syrota A (2001) Clinical impact of (18) F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42:1464–1469
Lumachi F, Tregnaghi A, Zucchetta P, Cristina Marzola M, Cecchin D, Grassetto G, Bui F (2006) Sensitivity and positive predictive value of CT, MRI and I-123 MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun 27:583–588
Okosieme OE et al (2009) The utility of radioiodine uptake and thyroid scintigraphy in the diagnosis and management of hyperthyroidism. Clin Endocrinol 72:122–127
Sarkar S (2016) Thyroid gland. In: Elgazzar AH (ed) Pathophysiologic basis of nuclear medicine, 3rd edn. Springer, New York, NY, pp 209–221
Spies WG, Wojtowicz CH, Spies SM, Shah AY, Zimmer AM (1989) Value of post-therapy wholebody I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose 1-131 therapy. Clin Nucl Med 14:793
Taillefer R, Boucher Y, Potvin C, Lambert R (1992) Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99 m-sestamibi (double-phase study). J Nucl Med 33:1801–1807
Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins R (1999) [18 F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated thyroglobulin levels. J Clin Endocrinol Metab 84:2291–2302
Acknowledgment
I would like to thank Dr. Khalid Khalafallah for coauthoring to this chapter.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Elgazzar, A.H., Alenezi, S. (2020). Nuclear Medicine in the Endocrine System. In: A Concise Guide to Nuclear Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-26064-4_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-26064-4_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-26063-7
Online ISBN: 978-3-030-26064-4
eBook Packages: MedicineMedicine (R0)